Mayo Clinic | Strategic Alliance Partners

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Chemo therapy delivered in the home of patients has shown feasibility and safety according to researchers at Mayo Clinic

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma.

A new study suggests that blocking the survival response after PARP inhibitor treatment could bolster their efficacy in ovarian cancer.

Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US.

Mayo Clinic researchers identified a previously unrecognized way lung tumors weaken the immune system.

A Mayo Clinic study demonstrated how treatment sequencing may affect survival in early-stage pancreatic cancer.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

MedEduChat, an EHR-integrated AI agent provided individualized prostate cancer education for patients according to researchers at Mayo Clinic.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

Cardiac surgery and airway reconstruction successfully treated rare cancer that spread to a patient's heart according to researchers at Mayo Clinic.

Ayalew Tefferi, MD, tirelessly advances medicine, driven by a philosophy that physical and intellectual journeys are one.

Patients were able to better manage symptoms with digital check-ins and remote care according to researchers at the Mayo Clinic.

Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Dual-antibody, off-the-shelf therapy showed deep durable responses in patients with extra medullary multiple myeloma according to Mayo Clinic researchers.

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Mayo Clinic researchers have found previously unknown genetic and cellular processes that occur in lung cancers that respond well to immunotherapy.

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes.

Mayo Clinic researchers have identified a protein that acts like a traffic controller for DNA, preventing damage during cell division.

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

The addition of molecular breast imaging to a 3D mammogram more than doubled the ability to find cancer in dense tissue, according to Mayo Clinic investigators.

Tanios S. Bekaii-Saab, MD, discusses sequencing decisions according to molecular subgroups in colorectal cancer.

New technology and facility expansions at the Mayo Clinic will soon enable it to treat nearly 75% more patients each year with even more precise and effective therapies.

A new study suggests that if a tumor shows activity in the TERT gene, it tends to recur more quickly, even if it looks low-grade under the microscope.

A shorter and less intense course of postoperative radiation plus chemotherapy was shown to be effective in HPV-positive oropharyngeal cancer.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.